1. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug
- Author
-
Betty Peng, Yang Tian, Choung U. Kim, Joy Y. Feng, Aesop Cho, Martijn Fenaux, Michel Perron, Debi Jin, Adrian S. Ray, Mei Yu, Kathryn M. Kitrinos, Stacey Eng, Kelly A. Wong, Magdeleine Hung, Karin S. Ku, Gabriel Birkus, Guofeng Cheng, Weidong Zhong, Leanna Lagpacan, Bin Han, Yili Xu, Ona Barauskas, George Stepan, Anne Carey, Jason K. Perry, Neeraj Tirunagari, and Yu-Jen Lee
- Subjects
Cell Survival ,Hepatitis C virus ,viruses ,Hepacivirus ,Biology ,Viral Nonstructural Proteins ,medicine.disease_cause ,Virus Replication ,Antiviral Agents ,Virus ,chemistry.chemical_compound ,RNA polymerase ,Cell Line, Tumor ,medicine ,Humans ,Pharmacology (medical) ,Prodrugs ,NS5B ,Polymerase ,Pharmacology ,RNA ,Nucleosides ,Hep G2 Cells ,Prodrug ,Virology ,Molecular biology ,NS2-3 protease ,Infectious Diseases ,chemistry ,biology.protein - Abstract
As a class, nucleotide inhibitors (NIs) of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase offer advantages over other direct-acting antivirals, including properties, such as pangenotype activity, a high barrier to resistance, and reduced potential for drug-drug interactions. We studied the in vitro pharmacology of a novel C -nucleoside adenosine analog monophosphate prodrug, GS-6620. It was found to be a potent and selective HCV inhibitor against HCV replicons of genotypes 1 to 6 and against an infectious genotype 2a virus (50% effective concentration [EC 50 ], 0.048 to 0.68 μM). GS-6620 showed limited activities against other viruses, maintaining only some of its activity against the closely related bovine viral diarrhea virus (EC 50 , 1.5 μM). The active 5′-triphosphate metabolite of GS-6620 is a chain terminator of viral RNA synthesis and a competitive inhibitor of NS5B-catalyzed ATP incorporation, with K i / K m values of 0.23 and 0.18 for HCV NS5B genotypes 1b and 2a, respectively. With its unique dual substitutions of 1′-CN and 2′- C -Me on the ribose ring, the active triphosphate metabolite was found to have enhanced selectivity for the HCV NS5B polymerase over host RNA polymerases. GS-6620 demonstrated a high barrier to resistance in vitro . Prolonged passaging resulted in the selection of the S282T mutation in NS5B that was found to be resistant in both cellular and enzymatic assays (>30-fold). Consistent with its in vitro profile, GS-6620 exhibited the potential for potent anti-HCV activity in a proof-of-concept clinical trial, but its utility was limited by the requirement of high dose levels and pharmacokinetic and pharmacodynamic variability.
- Published
- 2014